CDT Equity Inc. has taken a significant step in its business strategy by entering into an Evaluation Agreement with Manoira Corporation. This agreement involves the issuance of shares to settle a payment, reflecting the company's commitment to advancing its pharmaceutical preparations.
The agreement, dated October 22, 2026, allows Manoira to analyze specific assets of CDT, including clinical stage compounds AZD1656 and AZD5904. The goal is to determine their potential to enhance Manoira's animal healthcare business. CDT issued 1,347,616 shares of common stock at a price of $0.1447, totaling $195,000, to settle this payment.
CDT Equity Inc., incorporated in Delaware, operates in the pharmaceutical preparations sector (SIC 2834). The company trades on the Nasdaq under the ticker symbols CDT and CDTTW. This recent filing is part of a series of disclosures, including a PRE 14A and other SEC forms, indicating ongoing activities and corporate governance matters.
According to the filing, the agreement includes standard representations and warranties customary for such contracts. Notably, Dr. Andrew Regan, the former CEO of CDT and a significant shareholder, is also the sole director of Manoira. However, he will not receive any compensation from the transactions outlined in the agreement.
In addition to the agreement with Manoira, CDT reported unregistered sales of equity securities. This includes the issuance of 397,374 shares to a service provider for consulting services and 437,779 shares to Sarborg Limited as per a prior securities purchase agreement. Furthermore, the company issued 499,616 shares to Dr. Regan in lieu of severance compensation following his resignation as CEO.
These developments could have broader implications for the pharmaceutical preparations industry, particularly as companies like CDT explore innovative partnerships and share issuances to enhance their portfolios. The filing does not specify what actions will follow this agreement, leaving stakeholders to anticipate the company's next steps.